Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a significant decline in short interest in August. As of August 14th, there was short interest totaling 714,471 shares, a decline of 40.5% from the July 30th total of 1,200,354 shares. Approximately 4.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 271,896 shares, the short-interest ratio is presently 2.6 days.

Cel-Sci Price Performance

Cel-Sci stock traded down $0.01 during trading hours on Monday, hitting $1.55. 29,748 shares of the stock were exchanged, compared to its average volume of 262,730. The stock has a market capitalization of $27.02 million, a P/E ratio of -0.16 and a beta of 0.63. The business’s 50-day moving average is $1.31 and its two-hundred day moving average is $2.40. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.42 and a current ratio of 1.48. Cel-Sci has a 12 month low of $0.89 and a 12 month high of $12.68.

Cel-Sci (NYSEAMERICAN:CVM) last posted its earnings results on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. State Street Corp lifted its position in Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after purchasing an additional 2,300 shares during the period. US Bancorp DE acquired a new stake in shares of Cel-Sci during the 3rd quarter worth approximately $80,000. HighTower Advisors LLC bought a new stake in shares of Cel-Sci during the fourth quarter worth approximately $53,000. HRT Financial LP acquired a new position in Cel-Sci in the fourth quarter valued at approximately $60,000. Finally, XTX Topco Ltd bought a new position in Cel-Sci in the fourth quarter valued at approximately $66,000. 12.08% of the stock is owned by institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.